Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
Provided By PR Newswire
Last update: Jan 13, 2025
– Opportunity to Define a New Myelofibrosis Treatment Paradigm with Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company On Track to Complete Enrollment in 1H 2025 –
Read more at prnewswire.com
